Resultats de la cerca - Tim Hagenacker

Refinar resultats
  1. 1
    Modulation of Voltage‐Gated Sodium Channels by Activation of Tumor Necrosis Factor Receptor‐1 and Receptor‐2 in Small DRG Neurons of Rats

    Modulation of Voltage‐Gated Sodium Channels by Activation of Tumor Necrosis Factor Receptor‐1 and Receptor‐2 in Small DRG Neurons of Rats per Markus Leo, S. Argalski, Maria Schäfers, Tim Hagenacker

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Understanding the burden of refractory myasthenia gravis

    Understanding the burden of refractory myasthenia gravis per Christiane Schneider‐Gold, Tim Hagenacker, Nico Melzer, Tobias Ruck

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Biomarkers in 5q-associated spinal muscular atrophy—a narrative review

    Biomarkers in 5q-associated spinal muscular atrophy—a narrative review per Hilmar Lapp, Maren Freigang, Tim Hagenacker, Markus Weiler, Claudia D. Wurster, René Günther

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    Patient-conducted anodal transcranial direct current stimulation of the motor cortex alleviates pain in trigeminal neuralgia

    Patient-conducted anodal transcranial direct current stimulation of the motor cortex alleviates pain in trigeminal neuralgia per Tim Hagenacker, Vera Bude, Steffen Naegel, Dagny Holle, Zaza Katsarava, Hans‐Christoph Diener, Mark Obermann

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of 2 different treatment approaches

    Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of 2 different treatment approaches per Christopher A. Scheiner, Masayuki Masuda, Tim Hagenacker, Lauren Powell, Pramoda Jayasinghe, Karissa Johnston, Karen S. Yee

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen

    Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen per Andreas Totzeck, Benjamin Stolte, Kathrin Kizina, Saskia Bolz, Melina Schlag, Andreas Thimm, Christoph Kleinschnitz, Tim Hagenacker

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy

    Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy per Benjamin Stolte, J Bois, Saskia Bolz, Kathrin Kizina, Andreas Totzeck, Melina Schlag, Christoph Kleinschnitz, Tim Hagenacker

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Schwann cells promote post-traumatic nerve inflammation and neuropathic pain through MHC class II

    Schwann cells promote post-traumatic nerve inflammation and neuropathic pain through MHC class II per Maike Hartlehnert, Angelika Derksen, Tim Hagenacker, David Kindermann, Maria Schäfers, Mathias Pawlak, Bernd C. Kieseier, Gerd Meyer zu Hörste

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy

    Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy per Benjamin Stolte, Andreas Totzeck, Kathrin Kizina, Saskia Bolz, Lena Pietruck, Christoph Mönninghoff, Nika Guberina, Denise Oldenburg, Michael Forsting, Christoph Kleinschnitz, Tim Hagenacker

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany

    Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany per Andreas Hahn, René Günther, Albert C. Ludolph, Oliver Schwartz, Regina Trollmann, Patrick Weydt, Markus Weiler, Kathrin Neuland, Martin Sebastian Schwaderer, Tim Hagenacker

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Clinical features and predictors of atrial fibrillation in patients with light‐chain or transthyretin cardiac amyloidosis

    Clinical features and predictors of atrial fibrillation in patients with light‐chain or transthyretin cardiac amyloidosis per Μαρία Παπαθανασίου, Aiste‐Monika Jakstaite, Sara Oubari, Johannes Siebermair, Reza Wakili, Julia Hoffmann, Alexander Carpinteiro, Tim Hagenacker, Andreas Thimm, Christoph Rischpler, Lukas Kessler, Tienush Rassaf, Peter Luedike

    Publicat 2022
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Quantitative 99mTc-DPD-SPECT/CT assessment of cardiac amyloidosis

    Quantitative 99mTc-DPD-SPECT/CT assessment of cardiac amyloidosis per Lukas Kessler, Pedro Fragoso Costa, David Kersting, Walter Jentzen, Manuel Weber, Peter Lüdike, Alexander Carpinteiro, Sara Oubari, Tim Hagenacker, Andreas Thimm, Tienush Rassaf, Ken Herrmann, Μαρία Παπαθανασίου, Christoph Rischpler

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival

    Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival per Sara Oubari, Ute Hegenbart, Renate Schoder, Maximilian Steinhardt, Μαρία Παπαθανασίου, Tienush Rassaf, Andreas Thimm, Tim Hagenacker, Eyad Naser, Ulrich Dührsen, Hans Christian Reinhardt, K. Martin Kortüm, Hermine Agis, Stefan Schönland, Alexander Carpinteiro

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale

    ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale per André Maier, Matthias Boentert, Peter Reilich, Simon Witzel, Susanne Petri, Julian Großkreutz, Moritz Metelmann, Paul Lingor, Isabell Cordts, Johannes Dorst, Daniel Zeller, René Günther, Tim Hagenacker, Torsten Grehl, Susanne Spittel, Joachim Schuster, Albert C. Ludolph, Thomas Meyer

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment

    Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment per Maren Freigang, Claudia D. Wurster, Tim Hagenacker, Benjamin Stolte, Markus Weiler, Christoph Kamm, Olivia Schreiber‐Katz, Alma Osmanovic, Susanne Petri, Alexander B. Kowski, Thomas Meyer, Jan Christoph Koch, Isabell Cordts, Marcus Deschauer, Paul Lingor, Elisa Aust, Daniel Petzold, Albert C. Ludolph, Björn Falkenburger, Andreas Hermann, René Günther

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients

    Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients per Christopher Nelke, Frauke Stascheit, Carmen Eckert, Marc Pawlitzki, Christina B. Schroeter, Niklas Huntemann, Philipp Mergenthaler, Ercan Arat, Menekse Öztürk, Dirk Foell, Stefanie Schreiber, Stefan Vielhaber, Asmae Gassa, Henning Stetefeld, Michael Schroeter, Benjamin Berger, Andreas Totzeck, Tim Hagenacker, Sven G. Meuth, Andreas Meisel, Heinz Wiendl, Tobias Ruck

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Eculizumab versus rituximab in generalised myasthenia gravis

    Eculizumab versus rituximab in generalised myasthenia gravis per Christopher Nelke, Christina B. Schroeter, Frauke Stascheit, Marc Pawlitzki, Liesa Regner-Nelke, Niklas Huntemann, Ercan Arat, Menekse Öztürk, Nico Melzer, Philipp Mergenthaler, Asmae Gassa, Henning Stetefeld, Michael Schroeter, Benjamin Berger, Andreas Totzeck, Tim Hagenacker, Stefanie Schreiber, Stefan Vielhaber, Hans‐Peter Hartung, Andreas Meisel, Heinz Wiendl, Sven G. Meuth, Tobias Ruck

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis

    Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis per Simon Witzel, André Maier, Robert Steinbach, Julian Großkreutz, Jan Christoph Koch, Anastasia Sarikidi, Susanne Petri, René Günther, Joachim Wolf, Andreas Hermann, Johannes Prudlo, Isabell Cordts, Paul Lingor, Wolfgang N. Löscher, Zacharias Kohl, Tim Hagenacker, Christian Ruckes, Birgit C. P. Koch, Susanne Spittel, Kornelia Günther, Sebastian Michels, Johannes Dorst, Thomas Meyer, Albert C. Ludolph

    Publicat 2022
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Clinical and genetic features of amyotrophic lateral sclerosis patients with<i>C9orf72</i>mutations

    Clinical and genetic features of amyotrophic lateral sclerosis patients with<i>C9orf72</i>mutations per Maximilian Wiesenfarth, Kornelia Günther, Kathrin Müller, Simon Witzel, Ulrike Weiland, Kristina Mayer, Christine Herrmann, Dávid Brenner, Joachim Schuster, Axel Freischmidt, Dorothée Lulé, Thomas Meyer, Martin Regensburger, Torsten Grehl, Alexander Emmer, Susanne Petri, Julian Großkreutz, Annekathrin Rödiger, Robert Steinbach, Thomas Klopstock, Peter Reilich, Florian Schöberl, Joachim Wolf, Tim Hagenacker, Ute Weyen, Daniel Zeller, Albert C. Ludolph, Johannes Dorst

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Guideline for the management of myasthenic syndromes

    Guideline for the management of myasthenic syndromes per Heinz Wiendl, Angela Abicht, Andrew Chan, Adela Della Marina, Tim Hagenacker, Khosro Hekmat, Sarah Hoffmann, Hans-Stefan Hoffmann, Sebastian Jander, Christian W. Keller, Alexander Marx, Arthur Melms, Nico Melzer, Wolfgang Müller‐Felber, Marc Pawlitzki, Jens‐Carsten Rückert, Ulrike Schara‐Schmidt, Christiane Schneider‐Gold, Benedikt Schoser, Bettina Schreiner, Michael Schroeter, B Schubert, Jörn-Peter Sieb, Fritz Zimprich, Andreas Meisel

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: